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Background: Loss of function mutations in SGPL1 are associated with
Sphingosine-1-phosphate lyase insufficiency syndrome, comprising steroid resistant
nephrotic syndrome, and primary adrenal insufficiency (PAI) in the majority of cases.
SGPL1 encodes sphingosine-1-phosphate lyase (SGPL1) which is a major modulator
of sphingolipid signaling.
Case Presentation: A Pakistani male infant presented at 5 months of age with
failure to thrive, nephrotic syndrome, primary adrenal insufficiency, hypothyroidism,
and hypogonadism. Other systemic manifestations included persistent lymphopenia,
ichthyosis, and motor developmental delay. Aged 9 months, he progressed rapidly into
end stage oligo-anuric renal failure and subsequently died. Sanger sequencing of the
entire coding region of SGPL1 revealed the novel association of a rare homozygous
mutation (chr10:72619152, c.511A>G, p.N171D; MAF−1.701e-05) with the condition.
Protein expression of the p.N171D mutant was markedly reduced compared to SGPL1
wild type when overexpressed in an SGPL1 knockout cell line, and associated with a
severe clinical phenotype.
Conclusions: The case further highlights the emerging phenotype of patients
with loss-of-function SGPL1 mutations. Whilst nephrotic syndrome is a recognized
feature of other disorders of sphingolipid metabolism, sphingosine-1-phosphate lyase
insufficiency syndrome is unique amongst the sphingolipidoses in presenting with
multiple endocrinopathies. Given the multi-systemic and progressive nature of this form
of PAI/ nephrotic syndrome, a genetic diagnosis is crucial for optimal management and
appropriate screening for comorbidities in these patients.
Keywords: SGPL1, sphingosine-1-phosphate lyase, congenital nephrotic syndrome, primary adrenal insufficiency,
multiple endocrinopathy
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INTRODUCTION
Sphingosine-1-phosphate lyase insufficiency syndrome (SPLIS) is
a recently described condition, which in the main, incorporates
steroid resistant nephrotic syndrome, and primary adrenal
insufficiency (PAI). The disease is associated with loss of function
mutations in SGPL1, encoding sphingosine-1-phosphate lyase
that irreversibly binds sphingosine 1-phosphate (S1P) and
commits it to the final degradative step in sphingolipid
metabolism (1–3). Phenotypic expression of the condition is
variable, from severe multi-systemic forms, associated with fetal
hydrops and early mortality, to isolated single organ disease
(1, 2, 4–9).
Nephropathy is associated with other genetic disorders of
sphingolipid metabolism, such as Fabry and Gaucher disease,
and sphingolipid accumulation is reported in glomerular
disease of non-genetic origin (10). Endocrinopathy, including
PAI, on the other hand is not commonly reported in the
sphingolipidoses (11).
We report the novel association of a rare variant in SGPL1 in a
patient presenting with a severe combination of primary adrenal
insufficiency and infantile onset nephrotic syndrome. This case
further highlights the emerging multi-systemic phenotype in this
rare disorder of sphingolipid metabolism, including its unique
association with wider endocrinopathy.
CASE PRESENTATION
A Pakistani male infant with 46XY karyotype, born to
consanguineous parents, presented at 5 months of age with
failure to thrive, metabolic acidosis and nephrotic syndrome,
unmasked by a transient diarrhoeal illness. Postnatal growth
failure was evident at presentation with a length of 58.5 cm
(−3.05 SDS) and weight of 5.25 kg (−3.16 SDS) and a history
of normal birthweight of 3.3 kg at 36 + 6 weeks gestation
(+0.69 SDS). He was noted to have palmar hyperpigmentation,
ichthyosis, under-virilized male genitalia and generalized
developmental delay. Laboratory investigations revealed initially
normal renal function, hypoalbuminaemia, mild lymphopenia,
and nephrotic range albuminuria. There was an initial high
anion gap metabolic acidosis which became normal anion gap
acidosis following intravenous rehydration. Transient glycosuria
and hypokalaemia prompted the consideration of proximal
renal tubular acidosis, however these values normalized with no
specific treatment other than rehydration and oral bicarbonate
medication (Table 1). Ultrasound scanning demonstrated
bilateral large, echogenic kidneys and calcification in both
adrenals. The patient was treated with captopril, 1-alfacalcidol,
sodium feredetate, ranitidine, bicarbonate 8.4% solution and
energy-dense oral and nasogastric feeding. Oedemawas relatively
mild and managed with as required diuretic medication; 20%
Human albumin infusions were not required.
The clinical phenotype and laboratory findings prompted
early endocrine review and the additional diagnosis of PAI
was made (low serum cortisol 61 nmol/L, markedly elevated
ACTH 999 ng/L and low normal aldosterone 190 pmol/L). A
wider endocrine phenotype included primary hypogonadism
TABLE 1 | Results of laboratory investigations at initial (5 months) and last
presentation (9 months).
Test (reference range) Acute
presentation
(district hospital)
At presentation
(Tertiary
hospital)
Last acute
presentation (9
months old)
UREA (2.5–6.0 mmol/L) 1.4 1 22.6
CREATININE (14–34 umol/L) 30 21 323
CYSTATIN C (0.7–1.5 mg/L) N/A 1.52 5.26
SODIUM (133–146 mmol/L) 137 139 138
POTASSIUM (3.5–5.0 mmol/L) 3.3-4.5 4.5 6.2
BICARBONATE (19–28 mmol/L) 13 16 33
CHLORIDE (95–108 mmol/L) 109 113 87
eGFR BY CREATININE
(ml/min/1.73m2 )
N/A 107 8
eGFR BY CYSTATIN-C N/A 48 15
CALCIUM (mmol/L) 2.31 2.11 1.51
PHOSPHATE (1.2–2.2 mmol/L) 1.97 1.79 2.74
PTH (1.6–6.9 pmol/L) 60 93.1 195.4
ALP (77–540 u/L) 524 505 198
ALBUMIN (28–40 g/L) 17 17 22
URINE PCR (0–30 mg/mmol) >2,000 2,189 1,975
URINE ACR (0–3.0 mg/mmol) N/A 1978.5 n/a
HEMOGLOBIN (100–130 g/L) 90 84 83
LYMPHOCYTES (3.3–11.5 ×
109/L)
0.9–1.6 1.52 0.58
PLATELETS (150–560 × 109/L) 391 457 415
CHOLESTEROL (1.2–4.7
mmol/L)
N/A 4.8 7.6
ACTH (0–46 ng/L)* 999
CORTISOL (133–537 nmol/l)* 61
LH (1.7–8.6 IU/L), FSH
(1.5–12.4 IU/L.)*
71, 27
TSH (0.2–5 mu/L)* 27
Free T4 (9–24 pmol/l)* 10.5
*Results prior to starting endocrine replacement therapy.
with microphallus and bilateral cryptorchidism (with raised
basal gonadotrophins FSH 71 IU/L, LH 27 IU/L) and
primary hypothyroidism (elevated TSH 25 mU/L and low fT4
10.7 pmol/L). Endocrine treatments included hydrocortisone,
fludrocortisone and L-thyroxine replacement. Multiple hospital
admissions ensued for nutritional and therapeutic interventions.
Renal function continued to deteriorate and the eGFR reduced
from 107 mls/min/1.73m2 at 5 months to 31 mls/min/1.73m2
by 8 months (Chronic Kidney Disease (CKD) stage IIIb).
Aged 9 months, the patient presented with acute oligo-
anuric renal failure and pulmonary oedema following a brief
diarrhoeal illness. Renal replacement therapy was declined by
the family given the burden of morbidity to date and the patient
subsequently died.
Initial genetic screening did not identify mutations within
the standard SRNS genetics panel (Bristol SRNS exome screen),
noting only a likely non-pathogenic, heterozygous missense
mutation in COL4A4 (NM_000092.4); Intron 41, c.3974-
4dupT which was not consistent with phenotype. The unusual
combination of nephrotic syndrome and primary adrenal
insufficiency prompted consideration of the recently published
multi-systemic syndrome of SGPL1 deficiency as a causative
disease mechanism (1, 2).
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MATERIALS AND METHODS
Sanger Sequencing
SGPL1 exons of interest (coding region) were amplified by PCR
using specific primers as previously described (2).
Sequence Interpretation and in silico
Analysis of Variants
Using an autosomal recessive disease model, variants were
assigned causality if they segregated within the proband family
and were deemed pathogenic based on several in silico prediction
software tools (SIFT; PolyPhen-2; Human Splicing Finder,
version 3.0). Minor Allele Frequency was determined from the
ExAC and Genome Aggregation Database (gnomAD) browsers.
Protein Structure Modeling
An online tool, G23D (http://www.sheba-cancer.org.il/G23D)
was used to map the genomic coordinates of pathogenic variant
and predict functional alterations to mutant protein structure.
In vitro Splicing Assay
An in vitro splicing assay was designed using the commercially
obtained Exontrap cloning vector pET01 (MoBiTec GmbH,
Göttingen, Germany) containing an intronic sequence
interrupted by a multiple cloning site. DNA fragments of
interest (insert length of 1,129 bp; exon 7 + 500 bp intronic
sequence at both 5′ and 3′ ends) were amplified using a
standard PCR protocol and specifically designed primers
containing a restriction enzyme target site for XbaI. PCR
products were sequenced, column purified using the QIAquick R©
PCR Purification Kit, and cloned into the Exontrap cloning
vector pET01 (MoBiTec GmbH). The cloned sequences were
verified by Sanger sequencing to ensure the fragment was in
the correct orientation using pET01 specific primers. Wild-type
(pET01-WT) and pET01 mutant plasmids were transfected into
HEK293T cells using Lipofectamine 2000 R© reagent (Thermo
Fisher Scientific). Total RNA, obtained from cells 24 h after
transfection, was subjected to RT-PCR to generate cDNA with
primer GATCCACGATGC (MoBiTec GmbH) and amplified
with primers within the 5′ and 3′ exons in the pET01 vector.
Amplification products were assessed on a 2% agarose gel.
Site Directed Mutagenesis
Site directed mutagenesis of SGPL1 Human Tagged ORF Clone
(Origene) and oligonucleotide primer design was performed
using the QuikChange II XL Site-Directed Mutagenesis Kit
(Agilent) and web based QuikChange program in keeping with
the manufacturer’s guidelines.
Western Blotting
CRISPR/ Cas9 engineered SGPL1 knockout H295R cells were
seeded into 6 well plates and transfected with wild type SGPL1
and p.N171D mutant constructs using Lipofectamine 2000 R©
reagent (Thermo Fisher Scientific). After 48 h whole cell lysates
were prepared by addition of RIPA buffer (Sigma Aldrich)
supplemented with protease and phosphatase inhibitor tablets
(Roche). Protein concentrations were quantified using a Bradford
protein assay (Bio-Rad). Lysates were denatured by addition of
Laemmli sample buffer 2X (Sigma Aldrich) and boiled for 5min
at 98◦C. 15–20 µg of protein were loaded into wells of a 4–
20% SDS-PAGE gel (Novex) prior to electrophoretic separation
using MOPS buffer. Protein transfer to PVDF membrane was
achieved by electro-blotting at 15V for 45min. The membrane
was blocked with 5% fat free milk in TBS/0.1% Tween-20 and
left to gently agitate for 1 h. Primary antibody (Human SGPL1
Antibody; AF5535, R&D Systems) was added at a concentration
of 1:500 and β-actin (1:10,000) used as a housekeeping control.
Primary antibody incubation was left overnight at 4◦C with
gentle agitation. The membrane was then washed for 5min (X3)
with Tris Buffered saline-Tween20 (TBST). Secondary anti-goat
and anti-mouse antibodies were added at a concentration of
1:5,000 to blocking buffer and the membrane incubated at 37◦C
for 60–90min. The membrane was subsequently washed three
times (5min each) with TBST and visualized with the LI-COR
Image Studio software for immune-fluorescent detection.
Study Approval
This study was approved by the Outer North East London
Research Ethics Committee, reference number 09/H0701/12.
Consent
Written informed consent was obtained from the parents or
guardians of the participant for participation in the study and the
publication of this case report.
RESULTS
Sanger sequencing of the entire coding region of SGPL1
revealed a very rare homozygous missense mutation in
SGPL1 (chr10:72619152, c.511A>G; p.N171D) (gnoMAD
MAF−1.701e-05; no homozygotes described) which was
heterozygous in the unaffected consanguineous parents and
siblings (Figures 1A,B). Partial alignment of SGPL1 protein
sequences showed conservation of asparagine (N) at position
171 across several species (Figure 1C). Single nucleotide
change c.511A>G (p.N171D), whilst denoted as deleterious
across several platforms (SIFT, PolyPhen), showed minor
conformational change on protein modeling that was likely to
lead to protein instability but with a relatively low reliability
score (Figure 2A). In silico prediction tools (Mutation Taster
and Human Splicing Finder 3.0) suggested creation of an
exonic splicing silencer site and aberrant splicing as the
underlying pathogenic mechanism. An in vitro splicing assay
revealed the mutant p.N171D heterologous mini-gene construct
demonstrated unaltered splicing with normal incorporation
of exon 7 between the constitutional exons of the exon trap
vector with removal of the intervening sequences (Figure 2B).
The p.N171D mutant plasmid generated by mutagenesis of
an SGPL1 Human ORF clone was expressed in a eukaryotic
CRISPR/Cas9 engineered SGPL1 KO H295R adrenocortical
cell line and protein expression quantified by western blotting
after 48 h. When compared to wild type, p.N171D was markedly
reduced suggesting reduced stability and increased susceptibility
to degradation in the mutant protein (Figure 2C).
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FIGURE 1 | Our patient harbors a homozygous mutation in SGPL1, c.511A>G, p.N171D. (A) Partial sequence chromatograms of genomic DNA from the parents
who are heterozygote carriers and the homozygote patient, showing the base change from A to G in exon 7. (B) Pedigree of affected patient. Black-filled symbols
indicate individual homozygous, half-filled indicate individuals heterozygous for the mutation. White-filled symbols indicate wild-type individuals. (C) Partial alignment of
SGPL1 protein sequences, showing conservation of asparagine (N) at position 171 across several species, highlighted in red, numbering relative to human sequence.
Sequence conservation is beneath the alignment, *total conservation, : partial conservation.
DISCUSSION
SGPL1 encodes sphingosine-1-phosphate lyase (SGPL1),
which provides the single exit point for the sphingolipid
metabolic pathway, irreversibly converting S1P to hexadecanal
and phosphoethanolamine. Sphingosine-1-phosphate lyase
insufficiency syndrome (SPLIS) describes the recently reported
multi-systemic disease associated SGPL1 deficiency (clinical
features summarized in Table 2) (1–9). Other mutations in
the sphingolipid pathway are related to the sphingolipidoses,
which include Gaucher, Fabry, and Niemann-Pick disease
amongst others. Sphingolipids play an integral role as structural
components of cell membranes, and sphingolipid intermediates
such as S1P, sphingosine, and ceramide are signaling molecules
involved in cell migration, differentiation, and cell survival.
SGPL1 deficiency leads to an accumulation of upstream
bioactive sphingolipids, often in a tissue-specific manner (1, 2, 9).
SGPL1 is found in the endoplasmic reticulum of renal podocytes,
mesangial, and endothelial cells and immunofluorescence studies
show co-localization in the renal proximal tubules, which may
explain the initial biochemical picture in our patient consistent
with proximal renal tubular dysfunction (1). Furthermore,
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FIGURE 2 | A conformational change in SGPL1 occurs with the p.N171D mutation, resulting in reduced protein expression. (A) Protein modeling showed a minor
conformational change in SGPL1 due to amino acid substitution at position 171, predicted to result in reduced protein stability. (B) An in vitro splicing assay showed
effective splicing of both wild type and mutant SGPL1 exon 7 constructs providing no evidence of aberrant splicing. (C) Expression of p.N171D mutant in an SGPL1
KO cell line is reduced when compared to wild type suggesting increased susceptibility to degradation.
it has been hypothesized that S1P accumulation leads to a
signaling defect of angiogenic factors, resulting in additional
changes within the renal parenchyma (6). The enzyme is
moderately expressed in the adrenal cortex, testes and thyroid
gland (2); the endocrine organs affected in our patient.
The sphingolipid intermediates have been implicated in the
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TABLE 2 | Summary of main clinical features of patients described with
genetically confirmed sphingosine-1-phosphate lyase insufficiency syndrome
(SPLIS) to date (1, 2, 4–9), including our own patient.
Patient
numbers
Patient details
Total patients 35 (+ 4 fetal
demise)
Initial presentation at ages varying postnatally
to 19 years
Sex (M:F) 21:14
Deaths 15 Age at demise varying postnatally, with fetal
hydrops, to 9 years; several precipitated by
septic episodes
Nephrotic
syndrome
29 Congenital to oldest presentation at 19 years
with SRNS, with 19 patients presenting in
infancy, six patients were reported to have
renal transplantation (two of these required a
second transplant).
Adrenal
insufficiency
23* (five
additional cases
with adrenal
calcification on
imaging)
Glucocorticoid deficiency in all cases ±
mineralocorticoid deficiency. Age at
presentation varying from early postnatal to
oldest at 11 years, 11 patients presenting in
infancy. 11 patients noted to have adrenal
calcifications on imaging.
Hypothyroidism 12 Primary hypothyroidism with mildly raised
TSH levels in all cases where biochemistry
was reported
Gonadal
dysfunction
7 Male patients presenting postnatally with
cryptorchidism ± microphallus, all with raised
gonadotrophins indicating primary gonadal
failure.
Ichthyosis 12
Neurological/
Developmental
delay
18 Phenotypically heterogenous, varying from
microcephaly, seizures, sensorineural
deafness to later presentation with abnormal
gait, peripheral neuropathy, progressive
neurological deficit. Central and peripheral
nervous system pathology variably reported.
Neuroimaging findings varied from corpus
callosum atrophy, cortical atrophy, cerebellar
hypoplasia to basal ganglia involvement.
Immunodeficiency 13 Most consistently this is an absolute
lymphopenia, some patients additionally with
hypogammaglobulinemia and neutropenia.
Other features <5 patients Dysmorphic features, skeletal abnormalities,
liver dysfunction are reported.
*Indicates biochemically proven.
regulation of acute steroidogenesis and expression of steroid
responsive transcriptional elements while SGPL1 deficient mice
have abnormal adrenal and testicular morphology (2, 12, 13), in
keeping with the phenotype seen in the human disease.
We present a novel association of a rare variant within
SGPL1 associated with a severe phenotype of SGPL1 deficiency,
encompassing infantile-onset nephrotic syndrome with a wider
endocrine phenotype including PAI, primary hypothyroidism
and primary hypogonadism. In addition, our patient also
demonstrated persistent mild lymphopenia, ichthyosis, and
neurodevelopmental delay, features similar to previously
described cases.
To date, there have been 35 published genetically confirmed
cases involving 20 kindreds and 20 different mutations in
SGPL1 (including this patient, not including those with fetal
demise) (1, 2, 4–9) (see Tables 2, 3). Patients present with
congenital or steroid resistant nephrotic syndrome (see Tables 2,
3) and progress to end-stage renal disease with renal biopsy
histological findings of focal segmental glomerulosclerosis and
diffuse mesangial sclerosis. Similarly, the majority of affected
individuals have adrenal disease (see Tables 2, 3). SGPL1 has a
potential role to play in other endocrine tissues with emerging
reports of wider endocrinopathy (thyroid and testicular), as seen
in our patient (1, 2, 5–9). This appears to be unique to SPLIS in
comparison to other sphingolipidoses. In common with several
disorders of sphingolipid metabolism, ichthyosis is reported (1,
2, 9). Neurological dysfunction can affect both the central and
peripheral nervous system and is described with progressive
morbidity. Interestingly, mutations inherited in compound
heterozygosity have been associated with isolated peripheral
neuropathy akin to Charcot-Marie Tooth; the adult siblings
described do not have additional disease (4). Lymphopenia is
seen in some patients and is associated variably with an increased
frequency of infections (1, 2, 5, 9). SPLIS therefore encompasses
a clinically heterogenous phenotype, with the most severe cases
presenting with fetal hydrops, whilst others are affected with
single organ disease alone.
Despite in silico predictions, the p.N171D SGPL1 mutant
showed unaltered splicing in comparison to wild-type, however
protein expression was markedly reduced as was anticipated
by the instability predicted by protein modeling. Whilst all
functional characterizations of SGPL1 variants, described in
this condition so far, demonstrate markedly reduced protein
expression, clinical severity has not always correlated (1, 2). It
has been proposed that individuals with most severe phenotypes
harbor mutations within the active pyridoxal-dependent
decarboxylase domain (5), which is home to the variant in our
presented case (Table 3, Figure 3). However, milder phenotypes
characterized solely by axonal polyneuropathy (Charcot Marie
Tooth) due to mutations p.S361∗ and p.I184T also occur within
this region. As yet, there is no evident genotype- phenotype
correlation in SPLIS, with equally severe clinical phenotypes seen
in mutations outside the active region and in both frameshift
and missense mutations (Table 3, Figure 3). Phenotypic
heterogeneity is also evident in individuals with the same
SGPL1 variants, even within kindreds. Further investigation of
the genotype together with detailed clinical phenotyping (at
presentation and longitudinally) is required, as more individuals
are diagnosed. Establishing a genotype/ phenotype correlation is
further complicated by the consanguinity of the affected kindreds
and the likely presence of other genetic modifiers of disease.
The recent description of SPLIS finally provides a diagnostic
link for patients presenting with congenital NS and PAI. In view
of the reports of isolated adrenal or renal disease at presentation
it would be pertinent for SGPL1 to be considered in diagnostic
genetic panels for PAI/SRNS and certainly if seen in combination.
Given the phenotypic variability of this disease, the genetic
diagnosis may be crucial for confirming the clinical suspicion
and facilitating initiation of appropriate screening and treatment
for patients. Importantly, early consideration of this disease will
hasten identification of associated co-morbidities. This could, for
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TABLE 3 | Phenotypic characterization of mutations in SGPL1.
Mutation Deaths SRNS PAI Hypothyroidism Gonadal dysfunction Ichthyosis Neurological features Immunodeficiency
p.S3Kfs*11 1/4 + + + – + ± ±
c.261+1G>A – + + + + + + +
p.E132GU – + + – – + – –
p.N171D 1/1 + + + + + + +
p.I184T† – – – – – – + –
p.S202L9 – + – + – – + +
p.R222W 2/2 + + – – – ± ±
p.R222Q 1/9 + + – – – + ±
p.R278Gfs*17U – + + – – + – –
p.F290Lδ 1/1 + + + + + + +
p.L312Ffs*30 – + + – + – – –
p.A316T9 – + – + – – + +
p.Y331*δ 1/1 + + + + + + +
p.R340W 2/2 + + + – – – –
p.S346I 3/3 + + + – + + +
p.S361*† – – – – – – + –
p.F411Lfs*56 1/1 + + + + – + +
p.Y416C – + + + – – + +
p.R505* 2/2 + + – + – – –
p.F545del 1/1 + + + – + + +
U†9δdenotes compound heterozygous mutations.
Sources of published mutations: Lovric et al. (1), Prasad et al. (2); Atkinson et al. (4); Bamborschke et al. (5); Janecke et al. (6); Linhares et al. (7); Settas et al. (8); Taylor et al. (9).
Our patient’s mutation is denoted in red. + denotes presence in all; ± denotes presence in some but not all patients; – denotes absence of clinical feature. Deaths reported all occurred
at <10 years of age.
FIGURE 3 | Domain topology showing distribution of 20 published mutations.
instance, reduce the rate of CKD progression and minimize the
long-term complications of the associated endocrinopathy. The
published literature suggests that the prognosis for these patients
is poor with just under 50% mortality (15/35 reported cases, with
4 additional cases of fetal demise), the majority of those deaths
in the first year of life. Future research will potentially lead to
targeted genetic therapies but for now, a heightened awareness
of the syndrome will allow earlier recognition, reducing the time
to diagnosis and appropriate intervention and inform genetic
counseling for affected families.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation, to any
qualified researcher.
Frontiers in Pediatrics | www.frontiersin.org 7 April 2020 | Volume 8 | Article 151
Maharaj et al. SGPL1 Associated Nephropathy and Endocrinopathy
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the Outer North East London Research Ethics
Committee, reference number 09/H0701/12. Written informed
consent to participate in this study was provided by the
participants’ legal guardian/next of kin. Written informed
consent was obtained from the individual(s), and minor(s)’ legal
guardian/next of kin, for the publication of any potentially
identifiable images or data included in this article.
AUTHOR CONTRIBUTIONS
DW, DT, and IB recruited and clinically characterized
patient. AM, RP, and LM conducted Sanger sequencing
and analysis of data. AM conducted protein modeling and
functional analysis of the SGPL1 mutant described. DW,
AM, and RP prepared the draft manuscript. All authors
contributed to the discussion of results, edited, and approved the
final manuscript.
FUNDING
This work has been supported by the Medical Research Council
UK (Project Grant MR/K020455/1 to LM), Barts Charity (Project
Grant MGU0361 to LM), Medical Research Council (MRC)
UK/National Institute for Health Research (NIHR) Clinical
Academic Research Partner Grant (MR/T02402X/1 to RP),
Government of Trinidad and Tobago Research Fellowship
(to AM).
REFERENCES
1. Lovric S, Goncalves S, Gee HY, Oskouian B, Srinivas H, Choi WI,
et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with
ichthyosis and adrenal insufficiency. J Clin Invest. (2017) 127:912–
28. doi: 10.1172/JCI89626
2. Prasad R, Hadjidemetriou I, Maharaj A, Meimaridou E, Buonocore F, Saleem
M, et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal
insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest. (2017)
127:942–53. doi: 10.1172/JCI90171
3. Choi YJ, Saba JD. Sphingosine phosphate lyase insufficiency syndrome
(SPLIS): a novel inborn error of sphingolipid metabolism. Adv Biol Regul.
(2019) 71:128–40. doi: 10.1016/j.jbior.2018.09.004
4. Atkinson D, Nikodinovic Glumac J, Asselbergh B, Ermanoska
B, Blocquel D, Steiner R, et al. Sphingosine 1-phosphate lyase
deficiency causes Charcot-Marie-Tooth neuropathy. Neurology. (2017)
88:533–42. doi: 10.1212/WNL.0000000000003595
5. Bamborschke D, Pergande M, Becker K, Koerber F, Dötsch J,
Vierzig A., et al. A novel mutation in sphingosine-1-phosphate
lyase causing congenital brain malformation. Brain Dev. (2018)
40:480–3. doi: 10.1016/j.braindev.2018.02.008
6. Janecke AR, Xu R, Steichen-Gersdorf E, Waldegger S, Entenmann A, Giner
T, et al. Deficiency of the sphingosine-1-phosphate lyase SGPL1 is associated
with congenital nephrotic syndrome and congenital adrenal calcifications.
HumMutat. (2017) 38:365–72. doi: 10.1002/humu.23192
7. Linhares ND, Arantes RR, Araujo SA, Pena SDJ. Nephrotic syndrome and
adrenal insufficiency caused by a variant in SGPL1. Clin Kidney J. (2018)
11:462–7. doi: 10.1093/ckj/sfx130
8. Settas N, Persky R, Faucz FR, Sheanon N, Voutetakis A, Lodish M,
et al. SGPL1 deficiency: a rare cause of primary adrenal insufficiency.
J Clin Endocrinol Metab. (2019) 104:1484–90. doi: 10.1210/jc.2018-0
2238
9. Taylor VA, Stone HK, Schuh MP, Zhao X, Setchell KD, Erkan E. Disarranged
Sphingolipid Metabolism From Sphingosine-1-Phosphate Lyase Deficiency
Leads to Congenital Nephrotic Syndrome. Kidney International Reports
(2019). doi: 10.1016/j.ekir.2019.07.018
10. Merscher S, Fornoni A. Podocyte pathology and nephropathy
- sphingolipids in glomerular diseases. Front Endocrinol. (2014)
5:127. doi: 10.3389/fendo.2014.00127
11. Vantyghem MC, Dobbelaere D, Mention K, Wemeau JL, Saudubray JM,
Douillard C. Endocrine manifestations related to inherited metabolic diseases
in adults. Orphanet J Rare Dis. (2012) 7:11. doi: 10.1186/1750-1172-7-11
12. Lucki NC, Sewer MB. The interplay between bioactive
sphingolipids and steroid hormones. Steroids. (2010) 75:390–
9. doi: 10.1016/j.steroids.2010.01.020
13. Schmahl J, Rizzolo K, Soriano P. The PDGF signaling pathway
controls multiple steroid-producing lineages. Genes Dev. (2008)
22:3255–67. doi: 10.1101/gad.1723908
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Maharaj, Theodorou, Banerjee, Metherell, Prasad and Wallace.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pediatrics | www.frontiersin.org 8 April 2020 | Volume 8 | Article 151
